Briggs Morrison - 02 Feb 2023 Form 4 Insider Report for Syndax Pharmaceuticals Inc (SNDX)

Role
President, Head of R&D, Director
Signature
/s/ Michael A. Metzger, Attorney-in-fact
Issuer symbol
SNDX
Transactions as of
02 Feb 2023
Net transactions value
+$913,600
Form type
4
Filing time
03 Feb 2023, 16:02:06 UTC
Previous filing
21 Sep 2022
Next filing
08 Feb 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SNDX Stock Options (Right to buy) Award $913,600 +32,000 $28.55 32,000 02 Feb 2023 Common Stock 32,000 $28.55 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 1/48th of the shares subject to the option shall vest monthly over a four-year period.